Lung Cancer
Conference Coverage
VIDEO: Pivotal results nail osimertinib’s role in NSCLC
VIENNA – Osimertinib, a third-generation EGFR tyrosine kinase inhibitor that received U.S. marketing approval in November 2015 as second-line...
Conference Coverage
‘Vanishing’ role forecast for whole-brain irradiation for NSCLC metastases
VIENNA – Whole-brain irradiation plus chemotherapy can no longer be considered the standard of care in patients with multiple brain metastases...
Conference Coverage
Ganetespib fails to hit mark in phase III NSCLC trial
VIENNA – The addition of ganetespib to docetaxel for the treatment of advanced non–small cell lung cancer (NSCLC) did not live up to its earlier...
Conference Coverage
VIDEO: Checkpoint inhibitors show few efficacy, safety differences
VIENNA - The two subclasses of immune checkpoint inhibitor drugs showed very little basis for choosing between them by either efficacy or toxicity...
Conference Coverage
Nivolumab plus ipilimumab shines as first-line in advanced NSCLC
VIENNA – A combination of two immunotherapy agents with different mechanisms of action produced impressive efficacy and acceptable toxicities as...
Conference Coverage
VIDEO: Decision aids can relay relative risks to lung cancer patients
VIENNA – Many lung cancer patients would like to work with their physicians to reach a shared decision about their care, but often feel...
Conference Coverage
Centers of excellence program raises quality bar in lung cancer management
VIENNA – Effort aims to reduce outcome disparities in community cancer centers.
Conference Coverage
Checkpoint inhibitors for lung cancer figure prominently at WCLC 2016
Oncology Practice will be on-site this coming week at the 17th World Conference on Lung Cancer in Vienna.
From the Journals
In lung cancer screening, patient education works
Patients showed marked improvement in knowledge of screening criteria and potential harms after a counseling session, but the improvements faded...
Conference Coverage
Tumor markers may predict anti–PD-L1 treatment response
NATIONAL HARBOR, MD. – Density in tumors of two key immune cells may be a biomarker for response to an inhibitor of programmed death-ligand 1...
From the Journals
Tobacco-related cancer incidence, mortality drop
Tobacco-related cancer incidence and mortality rates dropped from 2004 to 2013, the Centers for Disease Control and Prevention reported in the...